Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Neurological conditions

Neurological symptoms common in COVID-19 patients, researchers say

Research has shown that neurological symptoms — such as dizziness, headache, and impaired taste and smell — are common in patients with COVID-19.

Open access article

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals stay informed about an issue of national importance.

To learn more about coronavirus, please visit:

Neurological symptoms common in COVID-19 patients researchers say

Source: Science Photo Library

Patients with COVID-19 commonly experience neurological conditions, such as dizziness, headache, and impaired taste and smell

Neurological symptoms are common in patients with COVID-19, particularly if they have a severe infection, research published in JAMA Neurology suggests (10 April 2020)[1].

The team used data on 214 patients with confirmed COVID-19 treated at one of three specialist care centres in Wuhan, China, between 16 January 2020 and 19 February 2020.

Overall, 78 patients (36.4%) had neurological manifestations, involving the central nervous system (e.g. dizziness, headache, impaired consciousness), peripheral nervous system (e.g. taste, smell or vision impairment, and nerve pain), or skeletal muscles. Among the 88 patients with severe infection, neurological symptoms were significantly more common than in those with non-severe infection (45.5% vs. 30.2%). They included acute cerebrovascular disease, impaired consciousness and skeletal muscle injury. 

The team said that the findings suggested that COVID-19 could affect the nervous system as well as the respiratory system, and that the receptor for the SARS-CoV-2 virus, ACE2, is expressed in neural and skeletal tissues. They noted that in some patients, their only symptoms were neurological in nature.

“During the epidemic period of COVID-19, when seeing patients with these neurologic manifestations, physicians should consider SARS-CoV-2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and prevention of transmission,” the authors concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207915

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.